A
Alicia Rodríguez-Gascón
Researcher at University of the Basque Country
Publications - 59
Citations - 2008
Alicia Rodríguez-Gascón is an academic researcher from University of the Basque Country. The author has contributed to research in topics: Medicine & Gene delivery. The author has an hindex of 19, co-authored 52 publications receiving 1419 citations.
Papers
More filters
Journal ArticleDOI
Solid lipid nanoparticles as non-viral vector for the treatment of chronic hepatitis C by RNA interference.
Josune Torrecilla,Ana del Pozo-Rodríguez,P. S. Apaolaza,María Ángeles Solinís,Alicia Rodríguez-Gascón +4 more
TL;DR: Vectors prepared with HA showed to be twice more effective than those prepared with DX, and differences in the intracellular trafficking may justify the higher efficacy of the HA-prepared vectors.
Journal ArticleDOI
Nucleic Acid Delivery by Solid Lipid Nanoparticles Containing Switchable Lipids: Plasmid DNA vs. Messenger RNA.
Itziar Gómez-Aguado,Julen Rodríguez-Castejón,Mónica Vicente-Pascual,Alicia Rodríguez-Gascón,Ana del Pozo-Rodríguez,María Ángeles Solinís Aspiazu +5 more
TL;DR: In this article, different solid lipid nanoparticle (SLN)-based vectors for delivery of mRNA and pDNA were evaluated in human retinal pigment epithelial cells (ARPE-19) and human embryonic kidney cells (HEK-293).
Journal ArticleDOI
Gene delivery in the cornea: in vitro & ex vivo evaluation of solid lipid nanoparticle-based vectors.
Mónica Vicente-Pascual,Andrea Albano,Andrea Albano,María Ángeles Solinís,Loredana Serpe,Alicia Rodríguez-Gascón,Federica Foglietta,Elisabetta Muntoni,Josune Torrecilla,Ana del Pozo-Rodríguez,Luigi Battaglia +10 more
TL;DR: Solid lipid nanoparticle-based vectors are promising gene delivery systems for corneal diseases, including inflammation.
Journal ArticleDOI
Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: Influence of residual renal function on PK/PD target attainment
Helena Barrasa,Amaia Soraluce,Arantxazu Isla,Alejandro Martín,Javier Maynar,Andrés Canut,José Ángel Sánchez-Izquierdo,Alicia Rodríguez-Gascón +7 more
TL;DR: The standard dose (600mg q12h) ensures a moderately high probability of treatment success in anuric patients when the infection is due to microorganisms with MIC≤2mg/L; in patients with residual renal function, the standard dose is insufficient, but 900mg q8h provide higher probability of Treatment success without compromising the safety.
Journal ArticleDOI
Targeting corneal inflammation by gene therapy: Emerging strategies for keratitis
Josune Torrecilla,Ana del Pozo-Rodríguez,Mónica Vicente-Pascual,María Ángeles Solinís,Alicia Rodríguez-Gascón +4 more
TL;DR: This review focuses on the progress and challenges of gene therapy to treat corneal inflammation, and presents the main nucleic acid delivery systems, including viral and non‐viral vectors, and the most studied strategies to address the therapy: control of neovascularization and regulation of pro‐ and anti‐inflammatory cytokines.